Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Convertible Debt (2021 - 2022)

China Pharma Holdings' Convertible Debt history spans 2 years, with the latest figure at $4.8 million for Q2 2022.

  • For Q2 2022, Convertible Debt changed N/A year-over-year to $4.8 million; the TTM value through Jun 2022 reached $4.8 million, changed N/A, while the annual FY2021 figure was $5.2 million, N/A changed from the prior year.
  • Convertible Debt reached $4.8 million in Q2 2022 per CPHI's latest filing, down from $5.0 million in the prior quarter.
  • In the past five years, Convertible Debt ranged from a high of $5.2 million in Q4 2021 to a low of $4.8 million in Q2 2022.